drugset / Trial / NCT05333276
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
NaSingle-groupOpen-labelTreatment
Summary
TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-programmed cell death protein 1 (PD-1) antibody.
Timeline
- Start
- 2022-07-29
- Primary completion
- 2023-12
- Completion
- 2024-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Penpulimab | Monoclonal antibody | — | Intravenous |
| Subject | TQB3602 | Unknown | — | Oral |